SCHEMBL303393

SCHEMBL303393

COc1ccc(-n2ncc3c(Br)cc(C)cc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 7/20 0.50
NR3C1 P04150 2/20 0.48
SMN1; SMN2 Q16637 7/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
XDH P47989 1/20 0.45
MAPT P10636 4/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
DPP4 P27487 1/20 0.42
MCHR1 Q99705 4/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 4/20 0.42
HTT P42858 3/20 0.42
TSHR P16473 2/20 0.42
POLB P06746 1/20 0.42
S1PR4 O95977 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304075 0.86 NR3C1 (0.50) NPBWR1NR3C1SMN1; SMN2KMT2AMEN1
SCHEMBL304064 0.83 NR3C1 (0.47) NR3C1SMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL303854 0.82 RAB9A (0.44) NR3C1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL13884790 0.80 ALDH1A1 (0.40) NR3C1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL4398029 0.77 NPC1 (0.49) NR3C1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL837429 0.71 CYP11B1 (0.52) NPBWR1NR3C1SMN1; SMN2KMT2AXDH
SCHEMBL1773970 0.70 NR3C1 (0.45) NR3C1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL9609001 0.70 NR3C1 (0.44) NPBWR1NR3C1KMT2AMEN1MCHR1
SCHEMBL304234 0.69 SCN9A (0.46)
SCHEMBL2008520 0.69 MAPK14 (0.42) NR3C1SMN1; SMN2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, MC2R NPBWR1 263/4885NR3C1 1/4885SMN1; SMN2 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.